Self-Study 2025 Release I Bundle

Type: Bundle•Format: On-demand

The 2025 BCOP Self-Study Bundle Release I offers 9.5 BCOP CE hours and ACPE CE hours. All self-study modules are on-demand and allow you to review and complete your learning at your convenience for up to one year following the release of the education.

This Self-Study Release I bundle contains the following modules:

  • Module 1: Treatment of Non-Melanoma Skin Cancers
  • Module 2: Anxiety and Depression in Adult Survivors of Cancer
  • Module 3: Targeting HER2 in Non-Breast Solid Tumors
  • Module 4: Germline Genetic Testing in Patients with Cancer
  • Module 5: Myeloproliferative Neoplasms - A Focus on JAK Inhibitors in Myelofibrosis

The modules may be completed in any order. Each contains an ACPE Pre-Test, Content Outline with accompanying articles, an ACPE and BCOP Post-Test, and a Course Evaluation. In order to claim BCOP credit, you must pass the BCOP Post-Test with a 75% or higher.

Get the bundle

Course Learning Objectives

UAN#: 0465-0000-25-067-H01-P

Author: Christine Barrett, PharmD, BCOP

Learning Objectives

  1. Summarize the efficacy data for immunotherapy in non-melanoma skin cancers
  2. Review the safety data for hedgehog pathway inhibitors in basal cell carcinoma
  3. Develop strategies for toxicity management of hedgehog pathway inhibitors

UAN#: 0465-0000-25-068-H99-P

Author: Lisa Grate, PharmD, MS, BCOP, BCPS

Learning Objectives

  1. Recognize risk factors, including disease, treatment and socioeconomic factors, that contribute to anxiety and depression in adult survivors of cancer
  2. Using validated assessment tools for anxiety and depression, formulate a therapeutic plan for addressing and monitoring anxiety and depression in adult survivors of cancer
  3. Develop recommendations regarding for the safe use of cannabis for anxiety and depression in adult survivors with cancer based on current evidence

UAN#: 0465-0000-25-069-H01-P

Author: Morgan L. Mace, PharmD, BCOP

Learning Objectives

  1. Identify the role and safety of trastuzumab deruxtecan for the treatment of HER2-positive solid tumors
  2. Demonstrate the appropriate place in therapy for tucatinib plus trastuzumab in HER2-positive metastatic colorectal cancer
  3. Examine the risks and benefits of trastuzumab deruxtecan for the treatment of HER2-mutant metastatic non-small-cell lung cancer

UAN#: 0465-0000-25-070-H99-P

Author: Amber B. Cipriani, PharmD, BCOP

Learning Objectives

  1. Discuss the prevalence and penetrance of germline cancer susceptibility variants in patients with cancer
  2. Recommend germline genetic testing in a person with cancer based on family history, cancer type, and somatic genetic testing results
  3. Explain the risks and benefits of germline genetic testing for cancer susceptibility

UAN#: 0465-0000-25-071-H01-P

Author: Matthew Newman, PharmD, MEHP, BCOP

Learning Objectives

  1. Interpret evidence supporting the use of newer JAK inhibitors in the management of myelofibrosis
  2. Identify hematologic and non-hematologic toxicities associated with JAK inhibitor therapy
  3. Choose an appropriate treatment plan for a patient with higher-risk myelofibrosis
Spacer Image

Knowledge Courses for Pharmacists

Technology requirements: HOPA Learn requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

acpe-bps-logos

HOPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. In order to claim BCOP credit, you must pass the BCOP Post- Test with a 75% or higher.

All CE hours will be transmitted to the CPE Monitor and BPS within 1-2 weeks of course completion.